Non-Hodgkin lymphoma (NHL) is a type of cancer that starts in the white blood cells known as lymphocytes. Protheragen has a remarkable group of researchers and scientists who have great experience in NHL. They are focused on developing new therapies for NHL, aiming to address unmet therapeutic needs and advance targeted therapeutics in the field.
Non-Hodgkin lymphoma (NHL) refers to a heterogeneous group of hematologic cancers arising from B cells, T cells, or natural killer (NK) cells. It accounts for nearly 4% of all cancers around the world. NHL has more than 60 distinct subtypes with diverse molecular, histological and clinical features. Among the more common subtypes are diffuse large B-cell lymphoma (DLBCL) which accounts for almost 30 percent of all NHL cases, follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Fig.1 Pathogenesis of B-cell non-Hodgkin lymphomas. (Klanova, Magdalena, and Pavel Klener., 2020)
The molecular mechanisms of non-Hodgkin lymphoma (NHL) are complex, involving gene mutations, epigenetic dysregulation, and microenvironmental interactions. Several key pathways associated with lymphomagenesis are highlighted below.
Gene Mutations
NHL is driven by recurrent genetic aberrations, including chromosomal translocations and somatic mutations. These alterations disrupt apoptosis, proliferation, and epigenetic regulation, contributing to malignant transformation.
Dysregulated Signaling Pathways
Constitutive activation of key pathways, such as the B cell receptor (BCR) signaling pathway and the NF-κB signaling pathway, promotes cell survival and proliferation.
Tumor Microenvironment (TME) Interactions
The TME supports NHL progression through immune evasion (PD-L1 upregulation), cytokine signaling (IL-6/IL-10), and stromal interactions.
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Rad001 + Rituximab | Blocks protein synthesis/cell proliferation and induces antibody-dependent cellular cytotoxicity (ADCC). | mTOR/CD20 | NCT01567475 | Phase I/II |
| Idelalisib + Rituximab | Disrupts B-cell signaling and induces ADCC. | PI3Kδ/CD20 | NCT01732913 | Approved |
| Glofitamab + Atezolizumab | Enhances anti-tumor immunity while blocking PD-L1-mediated immunosuppression. | CD20xCD3/ PD-L1 | NCT03533283 | Phase Ib/II |
| Lenalidomide | Enhances T/NK-cell activity and inhibits angiogenesis. | CRBN, TNF-α, IL-2, IFN-γ | NCT00179673 | Approved |
| Velcade + Temsirolimus | Induces apoptosis while blocking mTOR-driven cell proliferation and survival pathways in NHL. | Proteasome/mTOR | NCT01281917 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
As a specialized research service provider, Protheragen is committed to accelerating breakthroughs in rare lymphoproliferative disorders (LPDs), particularly non-Hodgkin lymphoma (NHL). Our end-to-end solutions span diagnostic development, novel therapeutic discovery, precision disease modeling, and rigorous preclinical validation. By leveraging cutting-edge technologies and validated NHL-specific models, we bridge the gap between research innovation and clinical translation, empowering partners to advance promising therapies from concept to commercialization.
| Types | Description |
|---|---|
| Transgenic Model | We introduced a transgenic BCR into the Eμ-MYC mouse strain to generate Eμ-MYC/BCRHEL transgenic mice, which develop tumors composed of mature naive B cells. |
| Xenograft Model | BALB/c mice were injected subcutaneously with A20 lymphoma cells to form tumors, mimicking the characteristics of non-Hodgkin lymphoma (NHL). |
Specializing in preclinical research for drug development, Protheragen offers a comprehensive solution that includes pharmacodynamics (PD), pharmacokinetic (PK) and toxicology studies to thoroughly validate and optimize therapies for non-Hodgkin lymphoma (NHL). If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)